Research programme: RTK antagonists - Beta PharmaAlternative Names: BPI-3119; Multi-RTKi
Latest Information Update: 21 Nov 2014
At a glance
- Originator Beta Pharma
- Mechanism of Action Receptor protein-tyrosine kinase antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Renal cell carcinoma
Most Recent Events
- 21 Nov 2014 Preclinical trials in Renal cell carcinoma (Metastatic disease) in USA (unspecified route)